BridgeMD
New treatment option for Diabetes Mellitus
Official title Prevalence of Diabetes-related Distress Among Patients Living With Type 2 Diabetes in a University Hospital Center and Identification of Its Associated Factors.
ClinicalTrials.gov ID: NCT07392437
What this study is testing
- What it's testing
- Diabetes-related distress is a psychological construct associated with poorer glycaemic control in people living with diabetes. In France, few data are available on this topic and none focus specifically on adults with type 2 diabetes.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults (age ≥ 18 years).
- Diagnosed with type 2 diabetes according to national (HAS) criteria, whether newly diagnosed or longstanding, with or without chronic complications...
- Able to understand the study information and to complete the self-administered questionnaires.
- Affiliated to the French social security system.
- Has not objected to participation in the study (non-opposition procedure).
You likely can't join if
- Age \< 18 years.
- Pregnant woman.
- Any type of diabetes other than type 2 diabetes (e.g. type 1 diabetes, secondary or genetic diabetes).
- Haemochromatosis.
- Cystic fibrosis.
- Current treatment with one of the following hyperglycaemic therapies: oral corticosteroids, immunosuppressive drugs, dopaminergic agonists...
See the full eligibility criteria
- Adults (age ≥ 18 years).
- Diagnosed with type 2 diabetes according to national (HAS) criteria, whether newly diagnosed or longstanding, with or without chronic complications, and with no restriction regarding HbA1c level. Managed for type 2...
- Able to understand the study information and to complete the self-administered questionnaires.
- Affiliated to the French social security system.
- Has not objected to participation in the study (non-opposition procedure).
- Age \< 18 years.
- Pregnant woman.
- Any type of diabetes other than type 2 diabetes (e.g. type 1 diabetes, secondary or genetic diabetes).
- Haemochromatosis.
- Cystic fibrosis.
- Current treatment with one of the following hyperglycaemic therapies: oral corticosteroids, immunosuppressive drugs, dopaminergic agonists, interferon-alpha, or protease inhibitors.
- History of partial or total pancreatectomy.
- Ongoing genetic work-up for atypical diabetes.
- Non-French-speaking patient.
- Major neurocognitive disorder or physical/mental disability preventing completion of the questionnaires.
- Adult under legal protection (guardianship or curatorship).
- Refusal or subsequent withdrawal of non-opposition.
- Any later paraclinical result finally revealing a type of diabetes other than type 2 diabetes.
The study team makes the final eligibility decision.
Where it's taking place
- Nice, France
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nice, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.